Shenzhen Chipscreen Biosciences Co., Ltd.

Shanghai Stock Exchange 688321.SS

Shenzhen Chipscreen Biosciences Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 161.88 M

Shenzhen Chipscreen Biosciences Co., Ltd. Total Non-Current Liabilities is USD 161.88 M for the year ending December 31, 2023, a 43.30% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Shenzhen Chipscreen Biosciences Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 112.97 M, a 292.33% change year over year.
Shenzhen Chipscreen Biosciences Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 28.79 M, a 119.68% change year over year.
Shenzhen Chipscreen Biosciences Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 13.11 M, a -15.32% change year over year.
Shenzhen Chipscreen Biosciences Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 15.48 M, a -32.58% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Shanghai Stock Exchange: 688321.SS

Shenzhen Chipscreen Biosciences Co., Ltd.

CEO	Dr. Xian-Ping Lu
IPO Date	Aug. 12, 2019
Location	China
Headquarters	Biology Incubator Building 2
Employees	1,057
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Vaccines

Description

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines that are in various research phase of the specific global intellectual property protection in three areas, such as cancer, metabolic diseases, and autoimmune diseases. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is based in Shenzhen, China.

Key trends

Past 5 years